Media Release
FOR IMMEDIATE RELEASE
IMV Inc. to Present at Upcoming Investor Conferences
Dartmouth, Nova Scotia; October 9, 2018 - IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that Chief Executive Officer Frederic Ors and Chief Financial Officer Pierre Labbé will present a corporate update at two upcoming investor conferences.
BIO Investor Forum, San Francisco, CA
-
Date: Thursday, October 18, 2018
-
Time: 9:00 a.m. PT
-
Location: The Elizabeth Room, Westin St. Francis
-
A live webcast of the presentation will be accessible via the following URL:
http://www.veracast.com/webcasts/bio/investorforum2018/15132412139.cfm.
Dawson James Small Cap Growth Conference, Jupiter, FL
-
Date: Tuesday, October 30, 2018
-
Time: 10:30 a.m. ET
-
Location: Track 2 - Preserve Ballroom B, Wyndham Grand Jupiter Hotel
-
A live webcast of the presentation will be accessible via the following URL:
http://wsw.com/webcast/dawson4/imv/.
Both webcasts will be archived for 90 days following the live presentation. A copy of the presentations will also be available on the Events, Webcasts & Presentations page of IMV’s website: www.imv-inc.com.
About IMV
IMV Inc., formerly Immunovaccine Inc., is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases. IMV is pioneering a new class of immunotherapies based on the Company’s proprietary drug delivery platform. This patented technology leverages a novel mechanism of action that enables the programming of immune cells in vivo, which are aimed at generating powerful new synthetic therapeutic capabilities. IMV’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the utility of the platform with a target: survivin. IMV is currently assessing DPX-Survivac as a combination therapy in multiple clinical studies with Incyte and Merck. Connect at www.imv-inc.com.
###